Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLNNOTCMKTS:INBPNASDAQ:ITRMOTC:ZOMDF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLNNClene$4.28-2.1%$3.24$2.28▼$8.20$39.26M0.4989,744 shs64,162 shsINBPIntegrated BioPharma$0.34+2.1%$0.30$0.16▼$0.42$10.23M0.7520,888 shs50,350 shsITRMIterum Therapeutics$0.99-0.7%$1.03$0.81▼$3.02$39.88M2.781.05 million shs343,326 shsZOMDFZomedica$0.04+1.2%$0.05$0.02▼$0.17$40.67M1.565.01 million shs1.17 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLNNClene-2.06%+4.39%+71.20%+3.38%-43.70%INBPIntegrated BioPharma+2.09%+8.71%+2.12%+8.71%+51.01%ITRMIterum Therapeutics-1.00%-0.09%+8.08%-31.25%-11.61%ZOMDFZomedica+1.22%-10.17%-11.70%-61.72%-75.10%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLNNClene2.4761 of 5 stars3.63.00.00.00.62.50.6INBPIntegrated BioPharma0.946 of 5 stars0.03.00.00.00.01.71.9ITRMIterum Therapeutics2.4807 of 5 stars3.55.00.00.02.60.00.0ZOMDFZomedica0.4161 of 5 stars0.05.00.00.01.10.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLNNClene 3.17Buy$40.00834.58% UpsideINBPIntegrated BioPharma 0.00N/AN/AN/AITRMIterum Therapeutics 3.00Buy$9.00809.09% UpsideZOMDFZomedica 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest INBP, ZOMDF, ITRM, and CLNN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025CLNNCleneBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$84.00 ➝ $33.005/8/2025CLNNCleneD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00 ➝ $23.005/8/2025ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$9.004/23/2025CLNNCleneJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$30.004/8/2025CLNNCleneD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00 ➝ $23.004/8/2025CLNNCleneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$31.00 ➝ $31.003/24/2025CLNNCleneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$31.00 ➝ $31.003/24/2025CLNNCleneD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00 ➝ $23.00(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLNNClene$340K113.04N/AN/A($1.06) per share-4.04INBPIntegrated BioPharma$50.32M0.21$0.05 per share7.45$0.64 per share0.53ITRMIterum TherapeuticsN/AN/AN/AN/A($0.15) per shareN/AZOMDFZomedicaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLNNClene-$39.40M-$4.04N/AN/AN/A-8,306.00%-1,106.30%-105.11%8/6/2025 (Estimated)INBPIntegrated BioPharma$110K$0.048.43∞N/A2.37%6.36%4.84%N/AITRMIterum Therapeutics-$24.77M-$0.99N/A∞N/AN/AN/A-71.37%8/13/2025 (Estimated)ZOMDFZomedicaN/A-$0.11N/A∞N/AN/AN/AN/AN/ALatest INBP, ZOMDF, ITRM, and CLNN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q3 2025INBPIntegrated BioPharmaN/A$0.02N/A$0.02N/A$13.95 million5/13/2025Q1 2025ITRMIterum Therapeutics-$0.14-$0.14N/A-$0.14N/AN/A5/7/2025Q1 2025CLNNClene-$1.10-$0.50+$0.60-$0.09$0.07 million$0.08 million3/24/2025Q4 2024CLNNClene-$1.21-$1.67-$0.46-$1.67$0.13 million$0.09 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLNNCleneN/AN/AN/AN/AN/AINBPIntegrated BioPharmaN/AN/AN/AN/AN/AITRMIterum TherapeuticsN/AN/AN/AN/AN/AZOMDFZomedicaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLNNCleneN/A1.361.36INBPIntegrated BioPharmaN/A3.721.70ITRMIterum TherapeuticsN/A3.723.58ZOMDFZomedicaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLNNClene23.28%INBPIntegrated BioPharma25.25%ITRMIterum Therapeutics9.21%ZOMDFZomedica8.95%Insider OwnershipCompanyInsider OwnershipCLNNClene35.30%INBPIntegrated BioPharma67.20%ITRMIterum Therapeutics9.20%ZOMDFZomedica5.58%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLNNClene1008.98 million5.81 millionOptionableINBPIntegrated BioPharma15030.98 million10.16 millionNot OptionableITRMIterum Therapeutics1040.00 million36.32 millionNot OptionableZOMDFZomedica50979.95 millionN/AN/AINBP, ZOMDF, ITRM, and CLNN HeadlinesRecent News About These CompaniesZomedica Corp.: Zomedica's Fourth Friday at Four Webinar Returns: Spotlight on TRUFORMA Diagnostic Platform - Revolutionizing In-Clinic DiagnosticsJune 19 at 12:59 PM | finanznachrichten.deZomedica's Fourth Friday at Four Webinar Returns: Spotlight on TRUFORMA Diagnostic Platform(R) - Revolutionizing In-Clinic DiagnosticsJune 19 at 6:30 AM | accessnewswire.comZomedica Launches Enhanced Equine Insulin Assay for the TRUFORMA(R) Diagnostic Platform Featuring an Extended Range and Automatic Sample DilutionMay 21, 2025 | accessnewswire.comZomedica Unveils Exclusive Fourth Friday at Four Webinar Series to Explore Cutting-Edge Veterinary InnovationsMay 19, 2025 | accessnewswire.comZomedica Corp (ZOMDF) Q1 2025 Earnings Call Highlights: Record Revenue Amid Strategic ChallengesMay 16, 2025 | finance.yahoo.comZomedica Corp. (ZOMDF) Reports Q1 Loss, Lags Revenue EstimatesMay 15, 2025 | zacks.comZomedica Announces First Quarter 2025 Financial Results: Revenue of $6.5 Million; 68% Gross Margin, and $65 Million in Liquidity to Support GrowthMay 15, 2025 | accessnewswire.comZomedica Launches Groundbreaking Equine Asthma Clinical Registry Featuring PulseVet(R) Shock Wave TherapyMay 13, 2025 | accessnewswire.comZomedica to Report First Quarter 2025 Financial Results with a Business Update on Thursday, May 15, 2025 at 4:30 pm ETMay 9, 2025 | accessnewswire.comZomedica CFO Scott Jordan Resigns, Interim Replacement NamedApril 30, 2025 | tipranks.comSponsored: Treating Animal Pain, Inflammation & Anxiety with Targeted Pulsed Electromagnetic Field TechnologyApril 14, 2025 | wfaa.comZomedica Corp. (ZOMDF)April 12, 2025 | finance.yahoo.comZomedica Corp. (ZOMDF): Among Stocks Insiders Were Buying In Q1 2025April 2, 2025 | finance.yahoo.comZomedica Corp. (ZOMDF): Among Stocks Insiders Were Buying In Q1 2025April 1, 2025 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeINBP, ZOMDF, ITRM, and CLNN Company DescriptionsClene NASDAQ:CLNN$4.28 -0.09 (-2.06%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$4.28 0.00 (0.00%) As of 06/20/2025 05:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.Integrated BioPharma OTCMKTS:INBP$0.34 +0.01 (+2.09%) As of 06/20/2025 03:25 PM EasternIntegrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical Businesses segment distributes healthful nutritional products for sale through mass market, grocery, drug, and vitamin retailers under the Peaceful Sleep and Wheatgrass brands, as well as other branded proprietary nutraceutical products. This segment also sells private label vitamin and nutritional supplement products through the Internet; provides warehousing and fulfilment services; and distributes fine natural botanicals, including multi minerals, as well as raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.Iterum Therapeutics NASDAQ:ITRM$0.99 -0.01 (-0.70%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.00 +0.01 (+1.01%) As of 06/20/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.Zomedica OTC:ZOMDF$0.04 +0.00 (+1.22%) As of 06/20/2025 03:59 PM EasternZomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and markets a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
